Wang Leyi, Wu Changdong, Hou Ming, Li Zhiwei
People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Clinical Laboratory Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Front Immunol. 2025 Sep 1;16:1642477. doi: 10.3389/fimmu.2025.1642477. eCollection 2025.
Sepsis and cancer interact in a complex, bidirectional manner that significantly impacts patient prognosis, with metabolic reprogramming being a key factor. Sepsis-induced immune dysregulation and metabolic changes promote immunosuppression, tumor growth, metastasis, and resistance to immunotherapy. Cancer patients, especially those on immunosuppressive therapies, are more vulnerable to sepsis, complicating treatment and worsening outcomes. An integrated approach combining immunotherapy, metabolic interventions, and antimicrobial strategies is essential, alongside identifying biomarkers for personalized care. Recent advancements emphasize the need to integrate molecular insights, immunotherapy, and drug sensitivity analysis. This review explores how sepsis-driven metabolic reprogramming affects cancer immunotherapy and metastasis, providing a foundation for future integrated treatment strategies. Further research should focus on developing precise therapies that regulate metabolism, immunity, and the microbiome.
脓毒症与癌症以复杂的双向方式相互作用，这对患者预后有重大影响，其中代谢重编程是一个关键因素。脓毒症诱导的免疫失调和代谢变化会促进免疫抑制、肿瘤生长、转移以及对免疫治疗的抗性。癌症患者，尤其是那些接受免疫抑制治疗的患者，更容易发生脓毒症，使治疗复杂化并恶化预后。将免疫治疗、代谢干预和抗菌策略相结合的综合方法至关重要，同时还需确定用于个性化治疗的生物标志物。最近的进展强调了整合分子见解、免疫治疗和药物敏感性分析的必要性。本综述探讨了脓毒症驱动的代谢重编程如何影响癌症免疫治疗和转移，为未来的综合治疗策略奠定基础。进一步的研究应专注于开发调节代谢、免疫和微生物群的精确疗法。
